ES2479565T1 - Poblaciones celulares que tienen actividad immunoreguladora, método para el aislamiento y usos - Google Patents
Poblaciones celulares que tienen actividad immunoreguladora, método para el aislamiento y usos Download PDFInfo
- Publication number
- ES2479565T1 ES2479565T1 ES12708032.3T ES12708032T ES2479565T1 ES 2479565 T1 ES2479565 T1 ES 2479565T1 ES 12708032 T ES12708032 T ES 12708032T ES 2479565 T1 ES2479565 T1 ES 2479565T1
- Authority
- ES
- Spain
- Prior art keywords
- cells
- population
- cell
- reg
- markers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims 8
- 230000004957 immunoregulator effect Effects 0.000 title 1
- 238000002955 isolation Methods 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims abstract 26
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000007787 solid Substances 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 2
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 2
- 239000006285 cell suspension Substances 0.000 claims 2
- 230000001413 cellular effect Effects 0.000 claims 2
- 208000037976 chronic inflammation Diseases 0.000 claims 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- -1 CD11c Proteins 0.000 claims 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 claims 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 1
- 102100022338 Integrin alpha-M Human genes 0.000 claims 1
- 102100022297 Integrin alpha-X Human genes 0.000 claims 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 210000000577 adipose tissue Anatomy 0.000 claims 1
- 239000006143 cell culture medium Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 210000005259 peripheral blood Anatomy 0.000 claims 1
- 239000011886 peripheral blood Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1352—Mesenchymal stem cells
- C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1352—Mesenchymal stem cells
- C12N2502/1382—Adipose-derived stem cells [ADSC], adipose stromal stem cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Población aislada de células madre mesenquimatosas caracterizada en que las células de dicha población no expresan CD112 y/o CD155.
Claims (1)
- REIVINDICACIONES1.Población aislada de células madre mesenquimatosas caracterizada en que las células de dicha población no expresan CD112 y/o CD155.52.Población celular según la reivindicación 1, caracterizada en que es positiva para al menos uno y preferiblemente todos de los siguientes marcadores de superficie: CD11b, CD11c, CD14, CD45, HLAII, CD31, CD34, CD45, 1B10 (αFSP), FceR1α y CD133.3.Un método para aislar una población celular según la reivindicación 1 que comprende los pasos de:10(i)preparar una suspensión celular de una muestra de tejido adiposo;(ii)recuperar las células de dicha suspensión celular;(iii)incubar dichas células en un medio de cultivo celular adecuado en una superficie sólida en condiciones que permitan que las células se adhieran a la superficie sólida y proliferen;15(iv)eliminar las células no adheridas;(v)seleccionar las células que después de ser pasadas al menos dos veces en tal medio permanecen adheridas a dicha superficie sólida; y(vi)determinar la presencia o ausencia de los marcadores CD112 y/o CD155 en células individuales o subpoblaciones20(vii)seleccionar las células o subpoblaciones negativas para los marcadores CD112 y/o CD155.4.Método para la preparación de una población de células T-reg que comprende:(a)poner en contacto una población celular según las reivindicaciones 1 o 2 con leucocitos de sangre 25periférica, y(b)seleccionar la población de células T-reg.5.Población aislada de células T-reg obtenible según el método de la reivindicación 4.306.Una composición farmacéutica que comprende una población celular según cualquiera de las reivindicaciones 1 a 2, o una población de células T-reg según la reivindicación 5, y un soporte farmacéuticamente aceptable.7.Uso de una población celular según cualquiera de las reivindicaciones 1 a 2, o una población de células T-reg según la reivindicación 5, o una composición celular farmacéutica según la reivindicación 6 para prevenir, 35tratar o mejorar uno o más síntomas asociados con enfermedades autoinmunitarias, trastornosinflamatorios o enfermedades inmunológicamente mediadas incluyendo rechazo de órganos y tejidos trasplantados.8.Un método para prevenir, tratar o mejorar uno o más síntomas asociados con enfermedades autoinmunitarias, trastornosinflamatorios o enfermedades inmunológicamente mediadas, en un sujeto que padece dichos 40trastornos o enfermedades, que comprende administrar a dicho sujeto en necesidad de tal tratamiento de una cantidad profiláctica o terapéuticamente aceptable de una población celular según cualquiera de las reivindicaciones 1 a 2, o una población de células T-reg según la reivindicación 5, o una composición celular farmacéutica según la reivindicación 6.459.Método según la reivindicación 8, en donde dicha enfermedad inflamatoria es una enfermedad inflamatoria crónica.10.Método según la reivindicación 9, en donde dicha enfermedad inflamatoria crónica se selecciona de enfermedad intestinal inflamatoria (EII) y artritis reumatoide (AR).5011.Un método para la selección de células según la reivindicación 1 que comprende los siguientes pasos:i)proporcionar una población de células madre mesenquimatosas que comprende células que tienen la capacidad de diferenciarse a al menos dos linajes celulares55ii)determinar la presencia o ausencia de los marcadores CD112 y/o CD155 en células o subpoblaciones dedicha población de células derivadas de tejido adiposoiii)seleccionar las células o subpoblaciones negativas para los marcadores CD112 y/o CD155.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11157930 | 2011-03-11 | ||
| EP11157930 | 2011-03-11 | ||
| PCT/EP2012/054251 WO2012123401A1 (en) | 2011-03-11 | 2012-03-12 | Cell populations having immunoregulatory activity, method for isolation and uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2479565T1 true ES2479565T1 (es) | 2014-08-20 |
Family
ID=45812789
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES12708032.3T Pending ES2479565T1 (es) | 2011-03-11 | 2012-03-12 | Poblaciones celulares que tienen actividad immunoreguladora, método para el aislamiento y usos |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20140154227A1 (es) |
| EP (1) | EP2683813A1 (es) |
| JP (1) | JP2014508527A (es) |
| KR (1) | KR20140016933A (es) |
| ES (1) | ES2479565T1 (es) |
| WO (1) | WO2012123401A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060045872A1 (en) | 2004-08-25 | 2006-03-02 | Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco | Use of adipose tissue-derived stromal stem cells in treating fistula |
| WO2014207679A1 (en) * | 2013-06-25 | 2014-12-31 | Tigenix S.A.U. | Cell populations having immunoregulatory activity, methods for the preparation and uses thereof |
| US20160161504A1 (en) * | 2013-08-01 | 2016-06-09 | Fundación Pública Andaluza Progreso Y Salud | Method for predicting treatment response and test for safe use of mesenchymal stem cells on inflammatory diseases |
| CN106460028B (zh) * | 2014-05-01 | 2020-03-10 | 株式会社岛津制作所 | 细胞的分化状态的评价方法 |
| US20170136065A1 (en) * | 2014-06-30 | 2017-05-18 | Tigenix S.A.U. | Mesenchymal stromal cells for treating rheumatoid arthritis |
| GB201604304D0 (en) | 2016-03-14 | 2016-04-27 | Tigenix S A U | Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease |
| CN110592002B (zh) * | 2019-10-10 | 2021-04-02 | 山东大学齐鲁医院 | 一种用于单细胞测序的膀胱尿路上皮单细胞悬液的制备方法及应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005056777A1 (ja) * | 2003-12-10 | 2005-06-23 | Hitachi Medical Corporation | 接着性幹細胞分画並びにその分離方法、品質管理方法及び品質管理装置 |
| JP4980211B2 (ja) * | 2004-05-12 | 2012-07-18 | ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ | 細胞単離方法 |
| US20060045872A1 (en) | 2004-08-25 | 2006-03-02 | Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco | Use of adipose tissue-derived stromal stem cells in treating fistula |
| EP2340847A3 (en) * | 2005-09-23 | 2016-11-09 | Cellerix, S.A. | Cell populations having immunoregulatory activity, method for isolation and uses |
| GB0820397D0 (en) * | 2008-11-07 | 2008-12-17 | Cellerix Sa | Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases |
-
2012
- 2012-03-12 ES ES12708032.3T patent/ES2479565T1/es active Pending
- 2012-03-12 US US14/004,004 patent/US20140154227A1/en not_active Abandoned
- 2012-03-12 WO PCT/EP2012/054251 patent/WO2012123401A1/en active Application Filing
- 2012-03-12 KR KR1020137026776A patent/KR20140016933A/ko not_active Application Discontinuation
- 2012-03-12 EP EP12708032.3A patent/EP2683813A1/en not_active Withdrawn
- 2012-03-12 JP JP2013557133A patent/JP2014508527A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140016933A (ko) | 2014-02-10 |
| JP2014508527A (ja) | 2014-04-10 |
| WO2012123401A1 (en) | 2012-09-20 |
| EP2683813A1 (en) | 2014-01-15 |
| US20140154227A1 (en) | 2014-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2479565T1 (es) | Poblaciones celulares que tienen actividad immunoreguladora, método para el aislamiento y usos | |
| Najar et al. | Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6 | |
| Han et al. | New insights into the heterogeneity and functional diversity of human mesenchymal stem cells | |
| Nagamura-Inoue et al. | Umbilical cord-derived mesenchymal stem cells: their advantages and potential clinical utility | |
| JP6755850B2 (ja) | 間葉系幹細胞の使用 | |
| Raicevic et al. | Influence of inflammation on the immunological profile of adult-derived human liver mesenchymal stromal cells and stellate cells | |
| US8647678B2 (en) | Anti-inflammatory macrophages and uses thereof | |
| Kang et al. | Immunomodulatory effects of human amniotic membrane-derived mesenchymal stem cells | |
| Götherström et al. | Fetal and adult multipotent mesenchymal stromal cells are killed by different pathways | |
| Kundrotas | Surface markers distinguishing mesenchymal stem cells from fibroblasts | |
| Avanzini et al. | Generation of mesenchymal stromal cells in the presence of platelet lysate: a phenotypic and functional comparison of umbilical cord blood-and bone marrow-derived progenitors | |
| Li et al. | Human amnion-derived stem cells have immunosuppressive properties on NK cells and monocytes | |
| Margossian et al. | Mesenchymal stem cells derived from Wharton's jelly: comparative phenotype analysis between tissue and in vitro expansion | |
| Lee et al. | Human bone marrow-derived mesenchymal stem cell gene expression patterns vary with culture conditions | |
| Najar et al. | Bone marrow mesenchymal stromal cells induce proliferative, cytokinic and molecular changes during the T cell response: the importance of the IL-10/CD210 axis | |
| Najar et al. | Mesenchymal stromal cells from the foreskin: tissue isolation, cell characterization and immunobiological properties | |
| JP2024023185A (ja) | エキソソームを単離するための胎盤の培養 | |
| Goligorsky | Endothelial progenitor cells: from senescence to rejuvenation | |
| Chen et al. | Gene delivery with IFN-γ-expression plasmids enhances the therapeutic effects of MSCs on DSS-induced mouse colitis | |
| Sargent et al. | CNS disease diminishes the therapeutic functionality of bone marrow mesenchymal stem cells | |
| KR20220024060A (ko) | 질환 치료용 엑소좀 | |
| Yan et al. | Intra-articular injection of human synovial membrane-derived mesenchymal stem cells in murine collagen-induced arthritis: assessment of immunomodulatory capacity in vivo | |
| JP2014508527A5 (es) | ||
| US20220218758A1 (en) | Quadri-positive stromal cell (qpsc) population for superior cell protection and immunomodulation | |
| Valencic et al. | The immunosuppressive effect of Wharton's jelly stromal cells depends on the timing of their licensing and on lymphocyte activation |